Results of consolidative radiotherapy for relapsed diffuse B-cell lymphoma

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
VIA MEDICA
Autores
Citação
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, v.28, n.5, p.601-607, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Recurrent diffuse large B-cell lymphoma (DLBCL) is a disease with high mortality. The standard of care involves autologous stem-cell transplantation (ASCT), which is not always feasible. We investigated the impact of radiotherapy as part of the salvage treatment for patients with relapsed disease. Materials and methods: Retrospective study of patients with recurrent DLBCL after chemotherapy and consolidative radiotherapy at a single institution. All patients were included if radiation was part of the first treatment. Results: Of 359 patients assessed between 2010 and 2017, 65 (18.1%) presented a recurrence, but only 62 received further treatment and were included in the study. Mean overall survival was 18.6 months since diagnosis and progression-free survival after first progression (PFS2) was 7.7 months. Patients were divided into two groups according to whether they did (24.8%) or did not (75.8%) receive radiation as part of their salvage treatment. Patients that did not receive R-CHOP (rituximab plus cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone) in the first line were treated more with radiation in the second line (p = 0.02). Six patients with in-field relapse were re-irradiated. Only 4 patients received ASCT as part of their treatment for relapsed disease. There was no difference in outcomes. Conclusion: There is a place for radiotherapy in the treatment of relapsed DLBCL, particularly when patients do not receive ASCT. Radiotherapy is well-tolerated. More trials to assess the role of radiotherapy for these patients are needed.
Palavras-chave
non-Hodgkin lymphoma, refractory lymphoma, radiotherapy
URI
https://observatorio.fm.usp.br/handle/OPI/59222
Referências
  1. Biswas T, 2010, INT J RADIAT ONCOL, V77, P79, DOI 10.1016/j.ijrobp.2009.04.036
  2. Fan JQ, 2023, RADIOTHER ONCOL, V183, DOI 10.1016/j.radonc.2023.109580
  3. Figura NB, 2022, EXPERT REV HEMATOL, V15, P1023, DOI 10.1080/17474086.2022.2147919
  4. FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404
  5. Gisselbrecht C, 2010, J CLIN ONCOL, V28, P4184, DOI 10.1200/JCO.2010.28.1618
  6. Jones G, 2022, ONCOLOGY-NY, V36, P718, DOI 10.46883/2022.25920980
  7. Krishnan A, 2005, BLOOD, V105, P874, DOI 10.1182/blood-2004-04-1532
  8. Medici CTM, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01589-1
  9. Ng AK, 2018, INT J RADIAT ONCOL, V100, P652, DOI 10.1016/j.ijrobp.2017.12.005
  10. Oehler-Jänne C, 2008, HEMATOL ONCOL, V26, P82, DOI 10.1002/hon.839
  11. Persky DO, 2008, J CLIN ONCOL, V26, P2258, DOI 10.1200/JCO.2007.13.6929
  12. PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305
  13. Sehn LH, 2015, BLOOD, V125, P22, DOI 10.1182/blood-2014-05-577189
  14. Wirth A, 2019, INT J RADIAT ONCOL, V103, P1158, DOI 10.1016/j.ijrobp.2018.12.006
  15. Yahalom J, 2005, EUR J HAEMATOL, V75, P90, DOI 10.1111/j.1600-0609.2005.00461.x
  16. Yeboa DN, 2015, J RADIOL ONCOL, V4, P11, DOI 10.1007/s13566-015-0182-y

Coleções
Artigos e Materiais de Revistas Científicas - HC/InRad